EMPLOYMENT AGREEMENTEmployment Agreement • October 3rd, 2013 • Aerie Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
This EMPLOYMENT AGREEMENT (the “Agreement”) is made this 20th day of September, 2013 (the “Effective Date”), by and between Aerie Pharmaceuticals, Inc., a Delaware corporation with principal executive offices at 135 US Highway 206, Suite 9, Bedminster, NJ 07921 (the “Company”), and Vicente Anido, Jr., Ph.D., residing at 1621 Bayside Dr., Corona del Mar, CA 92625 (the “Executive”).
AERIE PHARMACEUTICALS, INC. Bedminster, NJ 07921 December 15, 2011Aerie Pharmaceuticals Inc • October 3rd, 2013 • Biological products, (no disgnostic substances) • New Jersey
We are pleased to offer you, on the terms set forth in this letter (the “Agreement”), a position of employment as Chief Medical Officer of Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Your employment with the Company will start on January 2, 2012 (the “Start Date”).
AERIE PHARMACEUTICALS, INC. Bedminster, NJ 07921 September 24, 2012Aerie Pharmaceuticals Inc • October 3rd, 2013 • Biological products, (no disgnostic substances) • New Jersey
We are pleased to offer you, on the terms set forth in this letter (the “Agreement”), a position of employment as Chief Financial Officer (“CFO”) of Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Your employment with the Company will start on October 15, 2012 (the “Start Date”).
CONSULTING AGREEMENTConsulting Agreement • October 3rd, 2013 • Aerie Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New Jersey
THIS CONSULTING AGREEMENT (this “Agreement”), effective as of July 25, 2013 (“Effective Date”), is by and between THOMAS J. VAN HAARLEM, M.D., having an address at 14 Blue Cliff Drive, Lebanon, NJ 08833 (hereinafter referred to as “Consultant”) and AERIE PHARMACEUTICALS, INC., a Delaware corporation having offices at 135 US Highway 206, Suite 9, Bedminster, NJ 07921 (“Aerie” or the “Company”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 3rd, 2013 • Aerie Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of February 23, 2011 by and among Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and the persons and entities listed on Exhibit A attached hereto (the “Investors”).
SEPARATION AGREEMENT AND GENERAL RELEASESeparation Agreement and General Release • October 3rd, 2013 • Aerie Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New Jersey
This Separation Agreement and General Release (this “Agreement”), dated as of July 25, 2013, is entered into between THOMAS J. VAN HAARLEM, M.D. (the “Dr. van Haarlem”) and AERIE PHARMACEUTICALS, INC., a Delaware corporation (the “Company”).
FIRST AMENDMENT TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 3rd, 2013 • Aerie Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
This First Amendment to Amended and Restated Investors’ Rights Agreement (this “Agreement”) is dated as of December 7, 2012 and entered into by and among Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the entities listed on the signature pages hereto (each an “Investor” and, collectively, the “Investors”).
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • October 3rd, 2013 • Aerie Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is executed and delivered effective as of September 28, 2009 (“Amendment Effective Date”), by and between Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Casey Kopczynski, an individual resident of the State of North Carolina (“Employee”).
AERIE PHARMACEUTICALS, INC. Chapel Hill, North Carolina 27516 July 29, 2005Aerie Pharmaceuticals Inc • October 3rd, 2013 • Biological products, (no disgnostic substances) • North Carolina
We are pleased to offer you, on the terms set forth in this letter (the “Agreement”), a position as the Chief Operating Officer of Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”) as of the above date (the “Effective Date”).
